Department of Health and Human Services
Maine People Living Safe, Healthy and Productive Lives
Paul R. LePage, Governor
Ricker Hamilton, Acting Commissioner

Department of Health and Human Services
11 State House Station
Augusta, Maine 04333-0011
TTY Users: Dial 711 (Maine Relay)

DUR COMMITTEE AGENDA

Date: Tuesday, June 27, 2017
Time: 5:30PM to 8:30PM
Location: Augusta Armory, 179 Western Avenue, Augusta, ME

1) Call to Order

2) Introductions of New Committee Members

3) MaineCare Updates

4) Public Comments

5) Old Business

- Review of Minutes
- Make Elidel and Protopic preferred
- Retro-DUR: Additional data on Co-prescribing of stimulants, benzodiazepines and Z drugs

6) Closed Session

- Drug Financial Information Review

7) New Business (open session)

A. Retro-DUR
- Data presentation: Assessing the pattern of usage of long-acting stimulants, specifically looking at more than once a day dosing patterns and use among different age drugs, including pediatrics.

B. Retro-DUR

- Introduce: Co-prescribing of opiate pain medications (including cough syrups), benzodiazepines and “Z” drugs.

C. New Drug Review

Airduo
Alunbrig
Arymo ER
Austedo
Bavencio
Dupixent
Emflaza
Ingrezza
Kisqali
Lartruvo
Morphabond ER

Ocrevus
Rhofade
Rydapt
Spinraza
Synjardy XR
Trulance
Utibron
Xadago
Xermelo
Xultophy
Zejula

D. FDA Safety Alerts

FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects
https://www.fda.gov/Drugs/DrugSafety/ucm511530.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

Canagliflozin (Invokana, Invokamet): Drug Safety Communication - Increased Risk of Leg and Foot Amputations
https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm558605.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

FDA Drug Safety Communication: FDA identifies no harmful effects to date with brain retention of gadolinium-based contrast agents for MRIs; review to continue
https://www.fda.gov/Drugs/DrugSafety/ucm559007.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

FDA Drug Safety Communication: FDA restricts use of prescription codeine pain and cough medicines and tramadol pain medicines in children; recommends against use in breastfeeding women
https://www.fda.gov/Drugs/DrugSafety/ucm549679.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

FDA alerts consumers of nationwide voluntary recall of EpiPen and EpiPen Jr
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm550170.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

Information on Erythropoiesis-Stimulating Agents (ESA) Epoetin alfa (marketed as Procrit, Epogen), Darbepoetin alfa (marketed as Aranesp)
https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm109375.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

FDA approves two hepatitis C drugs for pediatric patients
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm551407.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

E. Next Meeting (Tuesday, September 12, 2017 from 5:30pm to 8:30pm)

F. Adjournment: 8:30PM